NIH Board Chair: Vaccine Clinic Adds No Budget, Risks Reputation

Patients with rare conditions who rely on the National Institutes of Health Clinical Center Research Hospital face a new layer of scrutiny over the institution's public image. The hospital's board chair warned that a recently opened vaccine injury clinic could damage the facility's reputation, a concern he raised during a scheduled board meeting.

Jack Leslie, who chairs the board overseeing the hospital, spent approximately six minutes criticizing Health and Human Services Secretary Robert F. Kennedy Jr. Leslie acknowledged that some board members might prefer silence, but he argued that staying quiet would be a failure of their advisory role. He stated that the secretary's anti-vaccine activities risk tarnishing a hospital widely known as the "house of hope" for patients who have exhausted other treatment options.

The criticism centered on Kennedy's surprise appearance at a ribbon-cutting ceremony for the new clinic. The event featured a panel of individuals who stated they were hurt by vaccines. These speakers sat behind placards reading "vaccine injured" while conversing with Kennedy and other senior Trump administration officials.

Leslie clarified that his objection was not to scientific inquiry. He affirmed that serious vaccine reactions are rare but real, and that individuals who believe they have been injured should be taken seriously. His focus remained on how the high-profile launch affects the hospital's standing rather than the merit of studying vaccine harms.

The new clinic represents a modest operational change rather than a major expansion. The NIH already maintains a center dedicated to studying vaccine injuries. Leslie noted that the new clinic arrives with no additional funding and no extra clinic space.

Jonathan Green, the hospital's chief executive officer, supported Leslie's assessment during the meeting. Green described the new clinic as just one more individual "protocol" within the hospital's existing operations. He reminded the board that the NIH has researched vaccine safety and efficacy for decades and that this work is continuing.

The remarks from both leaders highlight a distinction between the ceremonial launch and the clinic's actual resources. Leslie framed the issue as a reputational risk for a facility serving vulnerable patients, while Green presented the addition as a small component of long-standing research efforts.